Investor Overview Press Releases August 8, 2019 Aclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments August 1, 2019 Aclaris Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019 July 30, 2019 Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint View all » Events Aug 8, 20195:00 PM EDT Q2 2019 Aclaris Therapeutics Inc. Earnings Conference Call Jul 30, 20195:00 PM EDT Aclaris Presents Top-Line Data from AUAT-201 Oral Phase 2 Trial Jun 26, 20195:00 PM EDT Aclaris Presents Top-Line Data from AA-201 Topical Phase 2 Trial View all » Feature presentation Immuno-dermatology Pipeline Presentation October 2017
August 8, 2019 Aclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments
August 1, 2019 Aclaris Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019
July 30, 2019 Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint
